Therapeutic combinations comprising poly(ADP-ribose) polymerases inhibitor

Disclosed is the use of a compound of formula 1, or a pharmaceutically acceptable salt or solvate thereof, or a mixture thereof, in an amount from 1 to 48 mg/m2 free base, together with an anti-cancer agent chosen from gemcitabine, 6-thioguanine, doxorubicin, cisplatin, irinotecan, and temozolomide, for treating cancer in a mammal. Also disclosed is the use of a compound of formula 1, or a pharmaceutically acceptable salt or solvate thereof, or a mixture thereof, in an amount from 2 to 96 mg free base, together with an anti-cancer agent chosen from the same list as above, for treating cancer in a mammal. Also disclosed is a method for treating cancer in a non-human mammal comprising administering a compound of formula 1 or a pharmaceutically acceptable salt or solvate thereof, or a mixture thereof, in an amount effective to provide a sustained plasma concentration value of at least 5.9 ng/mL for at least 24 after administration, in combination with an anti-cancer agent as described above or a dose of radiation.